DE602005022673D1 - Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen - Google Patents

Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen

Info

Publication number
DE602005022673D1
DE602005022673D1 DE602005022673T DE602005022673T DE602005022673D1 DE 602005022673 D1 DE602005022673 D1 DE 602005022673D1 DE 602005022673 T DE602005022673 T DE 602005022673T DE 602005022673 T DE602005022673 T DE 602005022673T DE 602005022673 D1 DE602005022673 D1 DE 602005022673D1
Authority
DE
Germany
Prior art keywords
symptoms
estrogen receptor
vasomotoric
treatment
selective modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005022673T
Other languages
English (en)
Inventor
Robert Dean Dally
Jeffrey Alan Dodge
Scott Alan Frank
Ronald Jay Hinklin
Timothy Alan Shepherd
Owen Brendan Wallace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE602005022673D1 publication Critical patent/DE602005022673D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
DE602005022673T 2004-01-22 2005-01-18 Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen Active DE602005022673D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53834204P 2004-01-22 2004-01-22
US53844204P 2004-01-22 2004-01-22
PCT/US2005/000020 WO2005073204A1 (en) 2004-01-22 2005-01-18 Selective estrogen receptor modulators for the treatment of vasomotor symptoms

Publications (1)

Publication Number Publication Date
DE602005022673D1 true DE602005022673D1 (de) 2010-09-16

Family

ID=34830456

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005022673T Active DE602005022673D1 (de) 2004-01-22 2005-01-18 Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen

Country Status (20)

Country Link
US (2) US20090023917A1 (de)
EP (1) EP1709021B1 (de)
JP (1) JP4909086B2 (de)
KR (2) KR101008804B1 (de)
CN (1) CN102250042A (de)
AT (1) ATE476428T1 (de)
AU (1) AU2005207821B2 (de)
BR (1) BRPI0506721A (de)
CA (1) CA2551956C (de)
CR (1) CR8517A (de)
DE (1) DE602005022673D1 (de)
EA (2) EA012262B1 (de)
EC (1) ECSP066711A (de)
ES (1) ES2347973T3 (de)
IL (1) IL176738A0 (de)
MA (1) MA28436B1 (de)
NO (1) NO20063760L (de)
SG (1) SG149867A1 (de)
UA (1) UA85862C2 (de)
WO (1) WO2005073204A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436028T3 (es) 2006-06-23 2013-12-26 Radius Health, Inc. Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno
WO2008009079A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
CN102164908B (zh) * 2008-09-29 2013-08-28 伊莱利利公司 用于治疗骨关节炎的选择性雌激素受体调节剂
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
WO2011143469A1 (en) 2010-05-12 2011-11-17 Radius Health,Inc Therapeutic regimens
WO2012047617A1 (en) 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
FR3014437B1 (fr) * 2013-12-05 2016-12-23 Servier Lab Nouveau procede de synthese de l'agomelatine
FR3014434B1 (fr) * 2013-12-05 2015-12-25 Servier Lab Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
EP3834824A1 (de) 2014-03-28 2021-06-16 Duke University Verfahren zur behandlung von krebs unter verwendung von selektiven östrogenrezeptormodulatoren
KR101756050B1 (ko) 2015-03-04 2017-07-07 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
SI3507276T1 (sl) 2016-09-02 2022-01-31 Gilead Sciences, Inc. Spojine modulatorja toličnih receptorjev
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
CN108675999B (zh) * 2018-05-09 2021-03-16 浙江农林大学暨阳学院 一种醋酸铜催化制备8-(9-亚砜基-10-二氢菲)喹啉类化合物的方法
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
SI3820874T1 (sl) * 2018-07-12 2023-02-28 Eli Lilly And Company Selektivni razgrajevalci estrogenskih receptorjev
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
TW202300492A (zh) 2021-03-16 2023-01-01 美商美國禮來大藥廠 選擇性雌激素受體降解劑
WO2023150056A1 (en) 2022-02-01 2023-08-10 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5726186A (en) * 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
CA2213810C (en) * 1996-08-29 2006-06-06 Lewis Dale Pennington Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods
ID19392A (id) * 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
CA2217810A1 (en) * 1996-10-10 1998-04-10 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods
JP2001513501A (ja) * 1997-08-07 2001-09-04 イーライ・リリー・アンド・カンパニー エストロゲン阻害活性を有する１−［４−（置換アルコキシ）ベンジル］ナフタレン化合物
CN1668303B (zh) * 2002-07-22 2010-10-27 伊莱利利公司 含苯磺酰基的选择性雌激素受体调节剂

Also Published As

Publication number Publication date
CR8517A (es) 2006-12-01
MA28436B1 (fr) 2007-02-01
AU2005207821A1 (en) 2005-08-11
ATE476428T1 (de) 2010-08-15
ECSP066711A (es) 2006-10-31
BRPI0506721A (pt) 2007-05-02
US8217032B2 (en) 2012-07-10
KR20080016755A (ko) 2008-02-21
KR20060129277A (ko) 2006-12-15
AU2005207821B2 (en) 2011-02-10
EA012262B1 (ru) 2009-08-28
ES2347973T3 (es) 2010-11-26
KR101008804B1 (ko) 2011-01-14
KR100849559B1 (ko) 2008-07-31
SG149867A1 (en) 2009-02-27
EA016613B1 (ru) 2012-06-29
EA200601353A1 (ru) 2007-02-27
WO2005073204A1 (en) 2005-08-11
EP1709021A1 (de) 2006-10-11
EA200900586A1 (ru) 2009-08-28
JP4909086B2 (ja) 2012-04-04
CN102250042A (zh) 2011-11-23
CA2551956C (en) 2013-05-07
EP1709021B1 (de) 2010-08-04
JP2007519721A (ja) 2007-07-19
CA2551956A1 (en) 2005-08-11
US20090023917A1 (en) 2009-01-22
UA85862C2 (uk) 2009-03-10
US20110281847A1 (en) 2011-11-17
NO20063760L (no) 2006-10-16
IL176738A0 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
ATE476428T1 (de) Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen
ATE548039T1 (de) Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
EA201101475A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
SG155188A1 (en) Pyrrole derivatives as pharmaceutical agents
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
NO20084792L (no) Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
MX2009003981A (es) Agentes moduladores del receptor de calcio.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
TW200738669A (en) Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE555108T1 (de) Polyamide zur behandlung des menschlichen papilloma-virus
ATE399557T1 (de) Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
ATE432275T1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
CO6270359A2 (es) Moduladores de piperidinil y piperazinil de y-secretasa
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN